RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California. Show more
2570 West El Camino Real, Mountain View, CA, 94040, United States
Start AI Chat
Market Cap
33.04M
52 Wk Range
$0.70 - $1.45
Previous Close
$0.90
Open
$0.90
Volume
82,379
Day Range
$0.89 - $0.93
Enterprise Value
34.49M
Cash
10.04M
Avg Qtr Burn
-2.27M
Insider Ownership
4.64%
Institutional Own.
17.94%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|